The three fastest-growing trends in healthcare
The three fastest-growing trends in healthcare
Healthcare providers around the world are seeking to change the way that care is delivered to patients, due to increased pressure on budgets and higher demand for services.
A small minority of patients (with chronic or long-term conditions) often account for a large percentage of overall spending. By treating these patients more effectively and taking advantage of new technologies, healthcare providers can make significant cost savings.
Below are three of the fastest-growing trends in healthcare which can provide opportunities.
1. Glucose monitors
Wearable glucose monitors are one of the fastest new growth segments in healthcare. I think it is a great example of how technology can enable better monitoring of diabetic care, which is key to prevent patient complications.
For people with type 2 diabetes, wearable continuous glucose monitors reduce the need for finger-prick blood tests. This makes it much easier for sufferers of the condition to manage their health. The device uses a tiny sensor under the skin of the arm which is connected to a small transmitter patch on the surface of the skin.
The sensor reads blood sugar levels from fluid just beneath the skin and transmits them to your display device, which can be a hand-held device (such as a smartphone) or in the case of a type 1 diabetic, an insulin pump (known as an integrated system).
For many people, the first time they may have been aware of the device was when former UK prime minister Theresa May revealed one at the top of her left arm after she was pictured wearing a sleeveless dress during a dinner with US President Donald Trump in July 2018.
2. Drug therapy
In the past few years there have been huge medical breakthroughs in cancer treatments, transforming the way the disease is treated and leading to significantly higher survival rates.
Immunotherapy drugs, which work to treat cancer by harnessing the patient’s immune system, are the first group of drugs to have a significant impact on survival rates. The survival rate in advanced melanoma, for example, is now 20% to 30%, whereas previously it was less than 5%, according to the results of medical trials conducted by Merck. Survival rates in early stage lung cancer have also improved, with around 60% of patients treated with these drugs still alive after 18 months, compared with around 40% of those treated with chemotherapy, the Merck trials found.
This step change in cancer therapy has led to rapid adoption globally. Indeed, many of the big global drug companies, such as Roche, AstraZeneca and Bristol Myers, have been investing heavily in these type of drugs, which are increasingly becoming the new backbone of cancer treatments.
3. Gene therapy
Every year small numbers of children are born with gene mutations that tragically either lead to early death or developmental issues. Pre-natal/new-born screening and gene sequencing has enabled the early detection of these mutations.
The first gene therapy products have recently been approved that offer the potential of a one-time cure to correct or offset specific errant genes.
In May, Zolgensma was approved to treat spinal muscular atrophy, a neuromuscular disorder that leads to the loss of motor neurons and progressive muscle wasting. Half of babies diagnosed with the condition at birth die within 12 months.
The promise of gene therapy has been discussed for the past three decades but is only now the technology exists to make this a reality and highlights some of the new opportunities available in healthcare.
The opinions contained herein are those of the author and do not necessarily represent the house view. This document is intended to be for information purposes only. The material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The material is not intended to provide, and should not be relied on for, accounting, legal or tax advice, or investment recommendations. Information herein is believed to be reliable but Cazenove Capital does not warrant its completeness or accuracy. No responsibility can be accepted for errors of fact or opinion. This does not exclude or restrict any duty or liability that Cazenove Capital has to its customers under the Financial Services and Markets Act 2000 (as amended from time to time) or any other regulatory system. Cazenove Capital is part of the Schroder Group and a trading name of Schroder & Co. Registered Office at 1 London Wall Place, London EC2Y 5AU. Authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. For your security, communications may be taped and monitored.